Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HBM HoldingsFRA:6XY 64 PB Ratio is 3.55 as of Jul. 30, 2026, which is 72% above its 10-year median of 2.06. GuruFocus rates FRA:6XY with a GF Score™ of 64/100 and a GF Value™ of €0.74 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, HBM Holdings ranks worse than 58.88% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-30), HBM Holdings's share price is €1.33. HBM Holdings's Book Value per Share for the quarter that ended in Dec. 2025 was €0.38. Hence, HBM Holdings's PB Ratio of today is 3.55.
The historical rank and industry rank for HBM Holdings's PB Ratio or its related term are showing as below:
FRA:6XY'
s PB Ratio Range Over the Past 10 Years
Min: 0.39 Med: 2.06 Max: 12.97
Current: 3.56
During the past 8 years, HBM Holdings's highest PB Ratio was 12.97. The lowest was 0.39. And the median was 2.06.
FRA:6XY's PB Ratio is ranked worse than 58.88% of 1228
companies
in the Biotechnology industry
Industry Median: 2.69
vs FRA:6XY: 3.56
During the past 12 months, HBM Holdings's average Book Value Per Share Growth Rate was 158.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 51.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -5.40% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of HBM Holdings was 51.50% per year. The lowest was -30.40% per year. And the median was -17.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
HBM Holdings PB Ratio Related Terms
HBM Holdings PB Ratio Historical Data
* Premium members only.
The historical data trend for HBM Holdings's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HBM Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where HBM Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
HBM Holdings's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
HBM Holdings (FRA:6XY) has a PB Ratio of 3.55 as of Jul. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HBM Holdings and its competitors. This is 72% above median its historical median of 2.06. Over the past decade, HBM Holdings' PB Ratio has ranged from 0.39 to 12.97. According to the industry distribution chart, HBM Holdings ranks #723 out of 1228 companies in the Biotechnology industry, placing it in the top 58.9%.
Is HBM Holdings' PB Ratio too high?
HBM Holdings' current PB Ratio of 3.55 is 72% above median its 10-year median of 2.06. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 12.97. The Biotechnology industry median PB Ratio is 2.69. HBM Holdings' value of 3.55 is 32% above this industry median. Based on the distribution chart, HBM Holdings ranks #723 out of 1228 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HBM Holdings has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #723 out of 1228 companies for PB Ratio. This places HBM Holdings in the lower half of its industry. The industry median PB Ratio is 2.69. HBM Holdings' value of 3.55 is 32% above this benchmark. Historically, HBM Holdings' own PB Ratio has ranged from 0.39 to 12.97 over the past decade. While the company's 10-year median is 2.06 vs. the industry median of 2.69, HBM Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.69, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HBM Holdings's current PB Ratio of 3.55 is 32% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HBM Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HBM Holdings's current PB Ratio is 3.55, which is 72% above median its own 10-year median of 2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
Based on GuruFocus' analysis, HBM Holdings (FRA:6XY) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.74, compared to a current price of €1.33 — trading 79.7% above its estimated fair value. The current PB Ratio is 3.55, which is 72% above median its 10-year median of 2.06 and 32% above the Biotechnology industry median of 2.69. HBM Holdings' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For HBM Holdings (FRA:6XY), the current PB Ratio is 3.55 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (FRA:6XY) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of €1.33 is trading 79.7% above its estimated GF Value™ of €0.74.
GuruFocus considers HBM Holdings to be Significantly Overvalued.
Key valuation signals for FRA:6XY:
PB Ratio: 3.55 (72% above median its 10-year median of 2.06)
GF Value™: €0.74 vs. price of €1.33 (79.7% above fair value)
Industry Position: 32% above the Biotechnology median (#723 of 1228)
No single metric tells the full story. See the FRA:6XY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
64GF Score
Get the complete analysis for FRA:6XY
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6XY has been successfully added to your 
